PALI - Palisade Bio, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

PALI

PALISADE BIO, INC.

NASDAQ

$2.00

▼ DOWN 5.21% (-0.11)

KEY STATISTICS

Market Cap$347.16 M

52w High$2.86

52w Low$0.53

Dividend Yield—

Frequency—

P/E-1.90

Volume2.13M

Shares Out.173.58M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

J. D. Finley

COMPENSATION 2026

Salary$575,000

Stock Awards$17,736,572

Incentive Plan Pay$431,300

All Other Comp.$0

Total$18,790,257

ABOUT

SECTOR

Healthcare

WENT PUBLIC

March 30, 2007

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$7.00

Target Low$2.00

Target Median$4.50

Target Consensus$4.50

UPCOMING EARNINGS

DateNov 9, 2026

DayMonday

Rev. Est.$465.30K

NOV

MON

SPLIT RECORD

DATE	TYPE	RATIO
2024-04-08	Reverse	1:15
2022-11-16	Reverse	1:50
2021-04-28	Reverse	1:6
2019-07-18	Reverse	1:20
2017-01-09	Reverse	1:13

PRICE

$2.00 ▼ DOWN 5.21% (−$0.11)

OVERLAYS

About Palisade Bio, Inc.

https://www.palisadebio.com ↗

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company developing oral therapies like LB1148 to protect gut integrity during intestinal stress caused by various serious conditions.

INDUSTRY

Biotechnology

A PRODUCT PALISADE BIO, INC. IS KNOWN FOR

PALI-2108

PALI-2108 is Palisade Bio's oral, gut-restricted PDE4 inhibitor prodrug targeting the terminal ileum and colon for treating moderate-to-severe ulcerative colitis and fibrostenotic Crohn's disease.